CVS Health (NYSE: CVS) insider transactions
In the twelve months to 10 November 2026, executives and directors of CVS Health reported 8 open-market sales of 3,441,551 shares ($323.7m) and 1 open-market purchase of 23,855 shares ($2.0m), by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 November 2026 | Shah Prem S | EVP and Group President | Open-market purchase | +23,855 | $83.90 | 88,516 | Form 4 |
| 26 June 2026 | Clark James David | SVP, Cont & Chief Acct Officer | Shares withheld for tax | −454 | $90.98 | 27,606 | Form 4 |
| 31 May 2026 | Compton-Phillips Amy | EVP, Chief Medical Officer | Shares withheld for tax | −7,618 | $90.98 | 9,557 | Form 4 |
| 31 May 2026 | Newman Brian | EVP, Chief Financial Officer | Shares withheld for tax | −2,478 | $90.98 | 3,008 | Form 4 |
| 21 May 2026 | Aguirre Fernando | Director | Returned to the company | −1,563 | $93.50 | 10,513 | Form 4 |
| 21 May 2026 | Robbins Larry | Director | Open-market sale | −370,462 | $93.45 | 4,824,799 | Form 4 |
| 20 May 2026 | Aguirre Fernando | Director | Returned to the company | −30,437 | $93.78 | 12,076 | Form 4 |
| 20 May 2026 | Robbins Larry | Director | Open-market sale | −797,628 | $93.48 | 5,415,633 | Form 4 |
| 20 May 2026 | Robbins Larry | Director | Open-market sale | −152,691 | $94.81 | 5,262,942 | Form 4 |
| 20 May 2026 | Robbins Larry | Director | Open-market sale | −66,881 | $95.67 | 5,196,061 | Form 4 |
| 20 May 2026 | Robbins Larry | Director | Open-market sale | −800 | $96.28 | 5,195,261 | Form 4 |
| 19 May 2026 | Robbins Larry | Director | Open-market sale | −1,983,387 | $94.45 | 6,213,412 | Form 4 |
| 19 May 2026 | Robbins Larry | Director | Open-market sale | −151 | $95.18 | 6,213,261 | Form 4 |
| 14 May 2026 | Brown C David Ii | Director | Grant or award | +1,544 | $97.15 | 129,316 | Form 4 |
| 14 May 2026 | Sansone Guy P | Director | Grant or award | +1,447 | $97.15 | 15,106 | Form 4 |
| 14 May 2026 | Norwalk Leslie V | Director | Grant or award | +1,447 | $97.15 | 7,376 | Form 4 |
| 14 May 2026 | Kirby J Scott | Director | Grant or award | +1,447 | $97.15 | 14,434 | Form 4 |
| 14 May 2026 | Balser Jeffrey R. | Director | Grant or award | +2,058 | $97.15 | 15,717 | Form 4 |
| 14 May 2026 | Aguirre Fernando | Director | Grant or award | +1,563 | $97.15 | 42,513 | Form 4 |
| 8 May 2026 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | Open-market sale | −69,551 | $89.58 | 10,133 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the CVS Health page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.